Vyne Therapeutics INC Form 4 insider transactions

VYNE Therapeutics' Chief Legal Officer, Mutya Harsch, disposed of 3,581 common shares at $1.65 each to cover tax obligations related to restricted stock unit vesting, retaining 133,065 shares.

VYNE Therapeutics Inc. Chief Financial Officer Tyler Zeronda reported a routine disposition of 3,420 common shares at $1.65 per share to cover tax withholding requirements related to vested restricted stock units.

VYNE Therapeutics' Chief Scientific Officer, Iain Stuart, disposed of 2,453 shares of common stock at $1.65 per share to satisfy tax withholding obligations related to restricted stock unit vesting.

VYNE Therapeutics Inc. President and CEO David Domzalski reported a pre-planned disposition of 12,676 common shares at $1.65 per share, scheduled for June 30, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

Mutya Harsch, Chief Legal Officer and General Counsel of VYNE Therapeutics Inc., acquired 1,145 shares of common stock at $0.81 per share through the company's Employee Share Purchase Plan.

VYNE Therapeutics Inc.'s President and CEO, David Domzalski, acquired 8,681 shares of common stock at $0.81 per share through the company's Employee Share Purchase Plan.

Tyler Zeronda, CFO of Vyne Therapeutics, reports the disposal of 8,399 common stock shares to cover tax obligations related to vesting restricted stock units on March 31, 2025.

Chief Scientific Officer Iain Stuart disposed of 6,044 shares of Vyne Therapeutics Inc. to cover tax obligations related to vesting restricted stock units.

Mutya Harsch, Chief Legal Officer and GC of VYNE Therapeutics, disposed of shares to cover tax obligations related to vesting restricted stock units.

David Domzalski, CEO of VYNE Therapeutics, reports the disposal of shares to cover tax withholding requirements related to vesting restricted stock units.

Tyler Zeronda, CFO of Vyne Therapeutics Inc., was granted stock options to purchase 230,000 shares of common stock on January 21, 2025, according to a Form 4 filing.

Chief Scientific Officer Iain Stuart of Vyne Therapeutics Inc. received stock options for 230,000 shares at an exercise price of $2.77, vesting over four years.

Mutya Harsch, Chief Legal Officer and GC of VYNE Therapeutics Inc., acquired stock options for 230,000 shares on January 21, 2025, according to a Form 4 filing.

David Domzalski, CEO of VYNE Therapeutics, was granted stock options to purchase 730,000 shares of common stock.

Vyne Therapeutics director Patrick G. LePore purchased 15,000 shares of common stock at an average price of $2.92 on January 15, 2025.

Vyne Therapeutics' Chief Financial Officer, Tyler Zeronda, sold 4,675 shares of common stock to cover tax obligations related to vesting restricted stock units.

Vyne Therapeutics' Chief Scientific Officer, Iain Stuart, sold 4,857 shares of common stock to cover tax obligations related to vesting restricted stock units.

Mutya Harsch, Chief Legal Officer of Vyne Therapeutics, sold 4,697 shares of common stock to cover tax obligations related to vesting restricted stock units.

VYNE Therapeutics CEO, David Domzalski, sold 24,536 shares of common stock to cover tax obligations related to vesting restricted stock units.

Christine Borowski, a director at Vyne Therapeutics, was granted 20,000 stock options as part of her annual compensation.

Director Patrick G. Lepore of VYNE Therapeutics Inc. was granted 20,000 stock options at an exercise price of $2.40 per share.

A director of VYNE Therapeutics Inc. acquired 20,000 stock options at an exercise price of $2.40 per share.

Director Sharon Barbari of Vyne Therapeutics Inc. was granted 20,000 stock options as part of an annual award.

Elisabeth Sandoval, a director at Vyne Therapeutics, was granted 20,000 stock options at an exercise price of $2.40 per share.

A Vyne Therapeutics director, Anthony D. Bruno, acquired 20,000 stock options at an exercise price of $2.40, vesting on December 12, 2025.

Vyne Therapeutics CEO, David Domzalski, acquired 3,901 shares of common stock through the company's Employee Share Purchase Plan at a price of $2.1 per share.

Tyler Zeronda, CFO of Vyne Therapeutics, reports the disposal of 84 common stock shares to cover tax withholding requirements related to vesting restricted stock units.

Chief Scientific Officer Iain Stuart disposed of 109 shares of Vyne Therapeutics Inc. stock to cover tax withholding requirements related to vesting restricted stock units.

David Domzalski, CEO of VYNE Therapeutics, reports disposition of shares to cover tax obligations related to vesting of restricted stock units.

Mutya Harsch, Chief Legal Officer and GC of VYNE Therapeutics Inc., reports the withholding of shares to cover tax obligations related to vesting restricted stock units.